[Occupational Health Aspects of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC): Confirmation of Harmlessness].
Marienhospital, Klinik für Chirurgie, Ruhr-Universität Bochum, Herne, Deutschland.
A
A
Oyais
Marienhospital, Klinik für Chirurgie, Ruhr-Universität Bochum, Herne, Deutschland.
W
W
Solass
Marienhospital, Klinik für Chirurgie, Ruhr-Universität Bochum, Herne, Deutschland.
J
J
Zieren
Marienhospital, Klinik für Chirurgie, Ruhr-Universität Bochum, Herne, Deutschland.
M A
MA
Reymond
Marienhospital, Klinik für Chirurgie, Ruhr-Universität Bochum, Herne, Deutschland.
U
U
Giger-Pabst
D000062:Accidents, Occupational / Q000331:legislation & jurisprudence* / Q000517:prevention & control*; D000335:Aerosol Propellants / Q000008:administration & dosage* / Q000009:adverse effects*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects*; D058868:Compressed Air / Q000009:adverse effects*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects*; D005858:Germany; D006801:Humans; D008452:Maximum Allowable Concentration; D016273:Occupational Exposure / Q000331:legislation & jurisprudence* / Q000517:prevention & control*; D016272:Occupational Health / Q000331:legislation & jurisprudence; D010534:Peritoneal Neoplasms / Q000188:drug therapy*
D000335:Aerosol Propellants; D000970:Antineoplastic Agents; D004317:Doxorubicin; D002945:Cisplatin